Shares of Compugen Ltd. (NASDAQ:CGEN – Get Free Report) have been given an average recommendation of “Moderate Buy” by the five brokerages that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $5.00.
Several research analysts have recently commented on the company. Wall Street Zen cut Compugen from a “buy” rating to a “hold” rating in a research note on Saturday, May 23rd. Truist Financial raised Compugen to a “strong-buy” rating in a research note on Wednesday, March 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Compugen in a research note on Monday, April 20th. Lake Street Capital started coverage on Compugen in a research note on Tuesday, April 7th. They issued a “buy” rating and a $6.00 target price on the stock. Finally, Leerink Partners cut their target price on Compugen from $13.00 to $5.00 and set an “outperform” rating on the stock in a research note on Thursday, May 21st.
Read Our Latest Analysis on CGEN
Institutional Trading of Compugen
Compugen Price Performance
NASDAQ CGEN opened at $2.01 on Monday. The stock’s 50-day simple moving average is $2.58 and its two-hundred day simple moving average is $2.11. Compugen has a twelve month low of $1.30 and a twelve month high of $3.24. The company has a market capitalization of $190.05 million, a price-to-earnings ratio of 5.43 and a beta of 2.74.
Compugen (NASDAQ:CGEN – Get Free Report) last released its quarterly earnings data on Monday, May 18th. The biotechnology company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.01). The company had revenue of $2.18 million during the quarter, compared to analysts’ expectations of $1.57 million. Compugen had a return on equity of 47.72% and a net margin of 47.97%. On average, equities analysts expect that Compugen will post -0.28 earnings per share for the current fiscal year.
Compugen Company Profile
Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.
Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.
Read More
- Five stocks we like better than Compugen
- Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself?
- Rackspace’s AI Land Grab: Plugging Into the Next Compute Boom
- Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore
- Why Kroger’s Pullback Could Be a Gift for Patient Investors
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.
